拱东医疗(605369) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 254.47 million, a decrease of 33.15% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was CNY 27.29 million, down 72.12% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was CNY 27.92 million, a decline of 72.36% compared to the previous year[5]. - The basic earnings per share for Q3 2023 was CNY 0.25, down 71.59% from the same period last year[5]. - Total operating revenue for the first three quarters of 2023 was CNY 712,681,564.18, a decrease of 39.6% compared to CNY 1,179,652,625.55 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was CNY 88,249,716.27, a decline of 71.5% from CNY 308,448,671.69 in the same period of 2022[22]. - Basic and diluted earnings per share for the first three quarters of 2023 were CNY 0.79, compared to CNY 2.75 in the same period of 2022[22]. Cash Flow - The cash flow from operating activities for Q3 2023 was CNY 34.28 million, a decrease of 63.22% year-on-year[5]. - Cash inflow from operating activities for the first three quarters of 2023 was CNY 714,247,404.10, a decrease of 37.8% from CNY 1,148,154,333.39 in the same period of 2022[24]. - Cash outflow from operating activities for the first three quarters of 2023 was CNY 600,354,448.70, down 36.2% from CNY 940,747,002.35 in the previous year[24]. - The net cash flow from operating activities for Q3 2023 was ¥113,892,955.40, a decrease from ¥207,407,331.04 in Q3 2022[25]. - The company reported cash inflows from investment activities of ¥11,000,000.00 from recovered investments[25]. - The company incurred cash payments of ¥62,261,381.69 for the acquisition of fixed assets and other long-term assets[25]. - Cash flow from financing activities showed a net outflow of -¥34,734,526.73, compared to -¥155,126,406.60 in the same period last year[25]. Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 1,878.32 million, a slight increase of 0.58% compared to the end of the previous year[5]. - Current assets decreased to CNY 876,737,080.38 from CNY 1,133,588,796.73, reflecting a decline of approximately 22.6%[16]. - Total liabilities decreased to CNY 241,388,478.19 from CNY 262,885,088.21, a decline of approximately 8.2%[17]. - Total liabilities as of the end of the third quarter of 2023 were CNY 261,625,654.16, compared to CNY 275,298,695.27 at the end of the same period in 2022[21]. - Total equity attributable to shareholders of the parent company was CNY 1,616,690,910.67, an increase of 1.6% from CNY 1,592,189,533.03 in the previous year[21]. Operational Challenges - The company reported a significant decline in sales orders due to high sales base from special products sold in the previous year and inventory reduction by downstream customers[10]. - The company faced increased depreciation from investment projects and rising management and sales expenses as it seeks to expand into new markets and products[10]. - The company returned government subsidies amounting to CNY 1,006,400 due to calculation errors identified by the auditing bureau[9]. Shareholder Information - The number of common shareholders at the end of the reporting period was 8,455[12]. - The top shareholder, Shi Huiyong, holds 52.21% of the shares, totaling 58,800,000 shares[13]. Other Financial Metrics - The weighted average return on equity decreased by 4.16 percentage points to 1.67% in Q3 2023[5]. - Deferred income tax liabilities increased to CNY 18,040,419.85 from CNY 10,256,941.99 year-over-year[21]. - Other comprehensive income after tax for the first three quarters of 2023 was CNY 11,232,056.03, significantly higher than CNY 1,155,788.83 in the same period of 2022[22]. - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[27].